Galapagos and Gilead commence Phase II trial of filgotinib for uveitis

Belgian biotechnology firm Galapagos and its collaboration partner Gilead Sciences has commenced a Phase II clinical trial of filgotinib to treat patients suffering from uveitis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news